Poster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other cancer therapeuticsFavorable tolerability sets stage for Part 3 (dose optimization) of Phase 1 trial, already underway MONTREAL, May 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc.

海报强调持久的疾病稳定持续超过治疗完成结果表明，一种独特的多模式作用机制不同于其他癌症治疗方法。可避免的耐受性为第一阶段试验的第3部分（剂量优化）奠定了基础，该试验已于2024年5月23日在蒙特利尔进行（环球通讯社）——Theratechnologies Inc。

(“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced Phase 1 data demonstrating signs of long-term efficacy and a manageable safety profile of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in patients with solid tumors.

专注于创新疗法开发和商业化的生物制药公司（“Theratechnologies”或“the Company”）（TSX:TH）（纳斯达克：THTX）今天宣布了第一阶段数据，证明了其主要研究肽-药物缀合物（PDC）候选物sudocetaxel zendustortide（TH1902）在实体瘤患者中的长期疗效和可控安全性。

The data will be presented in a poster session on June 1, 9:00 AM-12:00 PM CDT (abstract #3081, poster board #226) at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, which is taking place May 31-June 4, 2024, in Chicago, IL. In an updated analysis from Parts 1 and 2 of an ongoing Phase 1 clinical trial, sudocetaxel zendusortide induced durable disease stabilization (up to 45 weeks) lasting beyond treatment completion.

这些数据将在2024年5月31日至2024年6月4日在伊利诺伊州芝加哥举行的2024年美国临床肿瘤学会（ASCO）年会上于CDT 6月1日上午9:00至下午12:00（摘要#3081，海报板#226）的海报会议上发布。在正在进行的1期临床试验的第1部分和第2部分的最新分析中，多西紫杉醇zendusortide诱导持续疾病稳定（长达45周），持续超过治疗完成。

The results suggest a unique, multimodal mechanism of action distinct from other cancer therapeutics, including induction of immune cell infiltration even in “cold” tumor models, inhibition of vasculogenic mimicry, targeting of chemotherapy-resistant cancer stem cells, and activation of the cGAS/STING immune pathway, among other actions.

结果表明，一种独特的多模式作用机制不同于其他癌症治疗方法，包括即使在“冷”肿瘤模型中也诱导免疫细胞浸润，抑制血管生成拟态，靶向化疗耐药的癌症干细胞，以及激活cGAS/STING免疫途径，以及其他行动。

Additionally, investigators observed an early efficacy signal primarily in female cancers (ovarian cancer, endometrial cancer, triple-negative breast cancer [TNBC]), with seven of 16 participants (44%) achieving a clinical benefit rate (complete response + part.

此外，研究人员观察到主要在女性癌症（卵巢癌，子宫内膜癌，三阴性乳腺癌[TNBC]）中的早期疗效信号，16名参与者中有7名（44%）达到临床获益率（完全缓解+部分）。